Zenith Drugs Balance Sheet Health
Financial Health criteria checks 4/6
Zenith Drugs has a total shareholder equity of ₹172.6M and total debt of ₹260.5M, which brings its debt-to-equity ratio to 150.9%. Its total assets and total liabilities are ₹979.4M and ₹806.8M respectively. Zenith Drugs's EBIT is ₹83.7M making its interest coverage ratio 4.6. It has cash and short-term investments of ₹36.1M.
Key information
150.9%
Debt to equity ratio
₹260.50m
Debt
Interest coverage ratio | 4.6x |
Cash | ₹36.06m |
Equity | ₹172.59m |
Total liabilities | ₹806.80m |
Total assets | ₹979.38m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ZENITHDRUG's short term assets (₹839.2M) exceed its short term liabilities (₹718.2M).
Long Term Liabilities: ZENITHDRUG's short term assets (₹839.2M) exceed its long term liabilities (₹88.6M).
Debt to Equity History and Analysis
Debt Level: ZENITHDRUG's net debt to equity ratio (130%) is considered high.
Reducing Debt: ZENITHDRUG's debt to equity ratio has reduced from 294.2% to 150.9% over the past 5 years.
Debt Coverage: ZENITHDRUG's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: ZENITHDRUG's interest payments on its debt are well covered by EBIT (4.6x coverage).